Knowledge cycle transforms therapeutic innovation

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 1, 2012, Pages 3-8

  Waldman, S A ^a   Terzic, A ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALDOSTERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; CHOLESTEROL ESTER TRANSFER PROTEIN; DENOSUMAB; DRUGS USED IN THE TREATMENT OF ADDICTION; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STEROID HORMONE; TESTOSTERONE; VACCINE; VANDETANIB;

ANTIANDROGEN THERAPY; BONE ATROPHY; BONE DENSITY; CAROTID ATHEROSCLEROSIS; CASTRATION RESISTANT PROSTATE CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; COCAINE DEPENDENCE; DECISION SUPPORT SYSTEM; DRUG DEPENDENCE; DYSLIPIDEMIA; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE NEED; HEALTH CARE QUALITY; HORMONE SYNTHESIS; HUMAN; KNOWLEDGE BASE; METHAMPHETAMINE DEPENDENCE; OSTEOPOROSIS; PATIENT CARE; PERSONALIZED MEDICINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; REGENERATIVE MEDICINE; REVIEW; RHEUMATOID ARTHRITIS; THYROID CANCER; TOBACCO DEPENDENCE;

ANIMALS; DIFFUSION OF INNOVATION; HUMANS; THERAPEUTICS; THERAPIES, INVESTIGATIONAL;

EID: 84055222715     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.299     Document Type: Review

References (30)

1. Dollery, C.T. The challenge of complexity. Clin. Pharmacol. Ther. 88, 13-15 (2010).
2. Waldman, S.A. & Terzic, A. Molecular therapeutics from knowledge to delivery. Clin. Pharmacol. Ther. 87, 619-623 (2010).
3. Waldman, S.A., Hohl, R.J., Kearns, G.L., Swan, S.J. & Terzic, A. Clinical pharmacology as a foundation for translational science. Clin. Pharmacol. Ther. 90, 10-13 (2011).
4. Waldman, S.A. & Terzic, A. Molecular therapy drives patient-centric health care paradigms. Clin. Transl. Sci. 3, 170-171 (2010).
5. Johnson, J.A., Cavallari, L.H., Beitelshees, A.L., Lewis, J.P., Shuldiner, A.R. & Roden, D.M. Pharmacogenomics: application to the management of cardiovascular disease. Clin. Pharmacol. Ther. 90, 519-531 (2011).
6. Pereira, N.L. & Weinshilboum, R.M. The impact of pharmacogenomics on the management of cardiac disease. Clin. Pharmacol. Ther. 90, 493-495 (2011).
7. Penn, M.S., Dong, F., Klein, S. & Mayorga, M.E. Stem cells for myocardial regeneration. Clin. Pharmacol. Ther. 90, 499-501 (2011).
8. Nelson, T.J. & Terzic, A. Induced pluripotent stem cells: an emerging theranostics platform. Clin. Pharmacol. Ther. 89, 648-650 (2011).
9. Terzic, A., Folmes, C.D., Martinez-Fernandez, A. & Behfar, A. Regenerative medicine: on the vanguard of health care. Mayo Clin. Proc. 86, 600-602 (2011).
10. Waldman, S.A. & Terzic, A. Clinical and translational science: from bench-bedside to global village. Clin. Transl. Sci. 3, 254-257 (2010).
11. Terzic, A. & Waldman, S.A. Translational medicine: path to personalized and public health. Biomark. Med. 4, 787-790 (2010).
12. Collins, F.S. Reengineering translational science: the time is right. Sci. Transl. Med. 3, 90cm17 (2011).
13. Lewiecki, E.M. & Bilezikian, J.P. Denosumab for the treatment of osteoporosis and cancer-related conditions. Clin. Pharmacol. Ther. 91, 123-133 (2012).
14. Bryce, A. & Ryan, C.J. Development and clinical utility of abiraterone acetate as an androgen synthesis inhibitor. Clin. Pharmacol. Ther. 91, 101-108 (2012).
15. Waldman, S.A. & Terzic, A. Cardiovascular health: the global challenge. Clin. Pharmacol. Ther. 90, 483-485 (2011).
16. Kovacic, J.C. & Fuster, V. Therapeutic transitions from complex coronary artery disease to promoting cardiovascular health: Challenges 2010-2020. Clin. Pharmacol. Ther. 90, 509-518 (2011).
17. Gutstein, D.E. et al. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin. Pharmacol. Ther. 91, 109-122 (2012).
18. Terzic, A. & Waldman, S.A. Chronic diseases: the emerging pandemic. Clin. Transl. Sci. 4, 225-226 (2011).
19. Scott, D.L. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin. Pharmacol. Ther. 91, 30-43 (2012).
20. Camilleri, M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin. Pharmacol. Ther. 91, 44-59 (2012).
21. Langmuir, P.B. & Yver, A. Vandetanib for the treatment of thyroid cancer. Clin. Pharmacol. Ther. 91, 71-80 (2012).
22. Michalski, J.M., Golden, G., Ikari, J. & Rennard, S.I. PDE4: A novel target in the treatment of chronic obstructive pulmonary disease. Clin. Pharmacol. Ther. 91, 134-142 (2012).
23. Shen, X.Y, Orson, F.M. & Kosten, T.R. Vaccines against drug abuse. Clin. Pharmacol. Ther. 91, 60-70 (2012).
24. Beltrami, A.P., Cesselli, D. & Beltrami, C.A. Stem cell senescence and regenerative paradigms. Clin. Pharmacol. Ther. 91, 21-29 (2012).
25. Jungebluth, P., Moll, G., Baiguera, S. & Macchiarini, P. Tissue-engineered airway: a regenerative solution. Clin. Pharmacol. Ther. 91, 81-93 (2012).
26. Park, S.J., Kushwaha, S.S. & McGregor, C.G.A. Stateof-the-art implantable cardiac assist device therapy for heart failure: bridge to transplant and destination therapy. Clin. Pharmacol. Ther. 91, 94-100 (2012).
27. Arrell, D.K. & Terzic, A. Network systems biology for drug discovery. Clin. Pharmacol. Ther. 88, 120-125 (2010).
28. Woollett, G.R. Innovation in biotechnology: current and future states. Clin. Pharmacol. Ther. 91, 17-20 (2012).
29. Holstein, S.A. & Hohl, R.J. Therapeutic additions and possible deletions in oncology in 2011. Clin. Pharmacol. Ther. 91, 15-17 (2012).
30. Waldman, S.A. & Terzic, A. Clinical translational science 2020: Disruptive innovation redefines the discoveryapplication enterprise. Clin. Transl. Sci. 4, 69-71 (2011).